Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Trial for the Safety and Efficacy of BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma

NCT05430945 is registered in ClinicalTrials.gov with Zhejiang University as lead sponsor.

NCT NCT05430945
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05430945 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Trial for the Safety and Efficacy of BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma
Lead sponsor
Zhejiang University
Phase
Phase 1
Overall status
Unknown status
Start date
June 20, 2022
Completion date
June 20, 2025
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

refractory multiple myeloma, relapse multiple myeloma